Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis

Clinical Nephrology

Volumn 80, Issue 1, 2013, Pages 67-71

  Mori, Mari ^a   Nwaogwugwu, Uzoamaka ^a   Akers, Gwendolyn R ^b   McGill, Rita L ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Indiana Regional Medical Center   (United States)

Author keywords

Anti GBM disease; Glomeru lonephritis; Goodpasture's syndrome; Mycophe nolate mofetil; Pulmonary hemorrhage

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; IRON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ANEMIA; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HEADACHE; HEMATURIA; HUMAN; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; LUNG HEMORRHAGE; NAUSEA; PLASMAPHERESIS; PROTEINURIA; RELAPSE; REMISSION; THORAX RADIOGRAPHY; TREATMENT REFUSAL; WEAKNESS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; FEMALE; FERTILITY PRESERVATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; ORGANS AT RISK; PLASMAPHERESIS;

EID: 84880647415     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107333     Document Type: Article

References (23)

1. Goodpasture E W. The signifcance of certain pulmonary lesions in relation to the etiology of infu-enza. Am J Med Sci. 1919; 158: 863-870. doi:10.1097/00000441-191911000-00012
2. Stanton MC, Tange JD. Goodpasture's syndrome (pulmonary haemorrhage associated with glo-merulonephritis). Australas Ann Med. 1958; 7: 132-144.
3. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967; 126: 989-1004. doi:10.1084/ jem.126.6.989
4. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG. Molecular architecture of the Goodpasture auto-antigen in anti-GBM nephritis. N Engl J Med. 2010; 363: 343-354. doi:10.1056/NEJMoa09105 00
5. Hudson BG, Kalluri R, Gunwar S, Weber M, Ball-ester F, Hudson JK, Noelken ME, Sarras M, Richardson WR, Saus J, Abrahamson DR, Glick AD, Haralson MA, Helderman JH, Stone WJ, Jacob son HR. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int. 1992; 42: 179-187. doi:10.1038/ki.1992.276
6. Ioachimescu OC, Stoller JK. Diffuse alveolar hemorrhage: diagnosing it and fnding the cause. Cleve Clin J Med. 2008; 75: 258-265. doi:10.3949/ ccjm.75.4.258
7. Lockwood CM, Boulton-Jones JM, Lowenthal RM, Simpson IJ, Peters DK. Recovery from Good pasture's syndrome after immunosuppres-sive treatment and plasmapheresis. BMJ. 1975; 2: 252-254. doi:10.1136/bmj.2.5965.252
8. Swainson C P, Robson JS, Urbaniak SJ, Keller AJ, Kay AB. Treatment of Goodpasture's disease by plasma exchange and immunosuppression. Clin Exp Immunol. 1978; 32: 233-242.
9. Filler G, Hansen M, LeBlanc C, Lepage N, Franke D, Mai I, Feber J. Pharmacokinetics of mycophe-nolate mofetil for autoimmune disease in children. Pediatr Nephrol. 2003; 18: 445-449.
10. Buell C, Koo J. Long-term safety of mycopheno-late mofetil and cyclosporine: a review. J Drugs Dermatol. 2008; 7: 741-748.
11. Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Garcia EI, Alonso JC, Gascó JM, Pou L, Piera L. Effcacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary glomerulonephritis - a multicenter study. Nephrol Dial Transplant. 2007; 22: 1351-1360. doi:10.1093/ndt/gf805
12. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103-1112. doi:10.1681/ASN.2008101 028
13. Appel AS, Appel GB. An update on the use of my-cophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009; 5: 132-142. doi:10.1038/ncpne ph1036
14. Hiemstra T F, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, Hauser T, Neumann I, Tesar V, Wissing KM, Pagnoux C, Schmitt W, Jayne DR; European Vasculitis Study Group (EUVAS). My-cophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010; 304: 2381-2388. doi:10.1001/jama.2010.1658
15. Osuna A, Garrido J. Cyclophosphamide-intoler-ant Wegener's granulomatosis successfully treated with mycophenolate mofetil. Acta Reumatol Port. 2008; 33: 224-228.
16. Preddie DC, Markowitz GS, Radhakrishnan J, Nickolas TL, D'Agati VD, Schwimmer JA, Gar-denswartz M, Rosen R, Appel GB. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol. 2006; 1: 718-722. doi:10.2215/CJN.01711105
17. Koukoulaki M, Goumenos DS. The accumulated experience with the use of mycophenolate mofetil in primary glomerulonephritis. Expert Opin In-vestig Drugs. 2010; 19: 673-687. doi:10.1517/13 543781003765461
18. Laskari K, Zintzaras E, Tzioufas AG. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil. Clin Exp Rheumatol. 2010; 28: 83-86.
19. García-Cantón C, Toledo A, Palomar R, Fernandez F , Lopez J, Moreno A, Esparza N, Suria S, Rossique P, Diaz JM, Checa D. Goodpasture's syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant. 2000; 15: 920-922. doi:10.1093/ ndt/15.6.920
20. Hu W, Liu Z, Ji D, Xie H, Gong D, Li L. Staphylo-coccal protein A immunoadsorption for Goodpas-ture's syndrome in four Chinese patients. J Nephrol. 2006; 19: 312-317.
21. Wechsler E, Yang T, Jordan SC, Vo A, Nast CC. Anti-glomerular basement membrane disease in an HIV-infected patient. Nat Clin Pract Nephrol. 2008; 4: 167-171. doi:10.1038/ncpneph0724
22. Deierhoi MH, Kauffman RS, Hudson SL, Barber WH, Curtis JJ, Julian BA, Gaston RS, Laskow DA, Diethelm AG. Experience with mycopheno-late mofetil (RS61443) in renal transplantation at a single center. Ann Surg. 1993; 217: 476-482. doi:10.1097/00000658-199 30 5010-00007
23. Charytan D, Torre A, Khurana M, Nicastri A, Stillman IE, Kalluri R. Allograft rejection and glomerular basement membrane antibodies in Al-port's syndrome. J Nephrol. 2004; 17: 431-435